
    
      The drug being tested in this study is called alkotinib. Alkotinib has been demonstrated to
      benefit people with ALK+ NSCLC.

      The study is a non-control study.

      The study will enroll approximately 104 participants. All participants will take alkotinib
      300mg throughout the study.

      This multi-center trial will be conducted in China. The overall time to participate in this
      study is 3 years. Participants will make multiple visits to the site, and 28 days after last
      dose of study drug for a follow-up assessment.
    
  